α
AlphaScala
StocksSignalsNEWAlpha ScoreBrokers
Sign InGet Started
α
AlphaScala

Professional trading analysis with publicly tracked portfolios on TipRanks. Real trades, real data.

Markets

ForexStocksCryptoCommodities

Tools

Stock ResearchMarket SignalsAlpha ScoreHedge Funds 13FInsider BuysAgentic TradingAI Broker MatcherBroker ReviewsPortfoliosFree IndicatorsBlogLearn TradingTrading Q&A

Account

Sign InDashboardNewsletterContact UsAdvertise

Legal

AboutEditorial PolicyCorrectionsTerms of ServicePrivacy PolicyRisk Disclaimer

Risk Warning: AlphaScala provides educational content only and is not a financial advisor. Trading and investing involves substantial risk of loss and is not suitable for all investors. Past performance does not guarantee future results. You should consult a licensed financial advisor before making investment decisions. See our full risk disclaimer.

For AI AgentsAlphaScala is agent-ready —skill.md·llms.txt
© 2026 ROGA AI LIMITED · Registered in Gibraltar · Unit G02, Eurocity, Europort Avenue, Gibraltar GX11 1AAAlphaScala — Built with data, not hype.
All Stocks/Technology/AKTS

Aktis Oncology, Inc.

AKTS
TechnologyCommunication Equipment Website
Alpha Score
61
Moderate
Signal SnapshotMarket signals →
Alpha Score
61 · Moderate
Alpha Score of 61 reflects moderate overall profile with moderate momentum, strong value, moderate qual...
Updated Apr 15
Insiders
No recent signal
No recent open-market insider buying or selling is in the current rollup.
Form 4
13F Holder
No holder data yet
Top institutional holders appear after 13F ingestion maps this ticker.
13F filings
Latest Filing
No filing digest
Recent 10-K, 10-Q, and 8-K summaries will appear here when available.
SEC digest
Price ChartPowered by TradingView
Ask about AKTSAI research agent
Alpha Score BreakdownHow it works →

Alpha Score of 61 reflects moderate overall profile with moderate momentum, strong value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Momentum
50
Weak
Value
96
Strong
Quality
60
Moderate
Sentiment
—
no data
Key StatisticsUpdated Apr 15
P/E Ratio
6.28
Forward P/E
—
PEG Ratio
—
EPS (TTM)
2.84
Dividend Yield
—
Beta
173.37
Revenue (TTM)
—
Net Margin
-226.20%
ROE
-47.53%
Debt / Equity
0.00
52W High
$22.40
52W Low
$0.00
About Aktis Oncology, Inc.

Akoustis Technologies Inc. is a technology company specializing in the design, development, manufacture, and sale of radio frequency (RF) filter products for the wireless industry across the Americas, Asia, Europe, and other international markets. It leverages proprietary bulk acoustic wave (BAW) technology, including its microelectromechanical system (MEMS)-based XBAW manufacturing process, to produce high-performance filters optimized for high power, high frequency, and wide bandwidth applications. The company operates through two primary segments: Fabrication Services, which offers engineering review and backend packaging services, and RF Filters, focused on amplifier and filter product sales. Its solutions serve critical applications in smartphones, tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense systems. Akoustis Technologies Inc. also provides complementary products such as surface acoustic wave resonators, crystal resonators and oscillators, ceramic products, and back-end semiconductor supply chain services. Headquartered in Huntersville, North Carolina, the company plays a specialized role in advancing RF front-end modules for next-generation wireless connectivity.

CEO
Mr. Kamran Cheema
Employees
117
Quick Facts
Exchange—
SectorTechnology
IndustryCommunication Equipment
Market Cap—
Avg Volume386.16K
Popular Stocks
AAPL
Apple Inc.
MSFT
Microsoft Corporation
NVDA
NVIDIA Corporation
AMZN
Amazon.com Inc.
GOOGL
Alphabet Inc. Class A
GOOG
Alphabet Inc. Class C
META
Meta Platforms Inc.
TSLA
Tesla Inc.
Key Dates

Earnings calendar coming soon. Subscribe to get notified when AKTS reports next.

Get earnings alerts →